RxDoctor Payments Data

Allie Whitley, DO

Family Medicine · Little River, SCNPI 1356870299

Payments from drug & device makers

$6,342in general payments, 2019–2025

Across 354 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$755
  • Novo Nordisk$696
  • GSK$530
  • AstraZeneca$528
  • AbbVie$518
  • Pfizer$367
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,31099%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,342 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$219,000
Medicare patients
463
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$227,549
EliquisApixaban113$134,572
MounjaroTirzepatide87$122,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$71,697
FarxigaDapagliflozin Propanediol43$62,839
JardianceEmpagliflozin56$62,164
RybelsusSemaglutide37$61,958
Repatha SureclickEvolocumab47$55,129
JanuviaSitagliptin Phosphate39$47,112
TrulicityDulaglutide23$41,617
XareltoRivaroxaban21$27,315
Bydureon BciseExenatide Microspheres13$10,463
Rosuvastatin Calcium608$9,537
Icosapent Ethyl16$8,164
Atorvastatin Calcium721$7,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$696$289,507145 claims
Lilly USA, LLCMounjaro, Trulicity$153$163,842110 claims
PfizerEliquis$367$134,572113 claims
GSKTrelegy Ellipta, Breo Ellipta$530$76,99172 claims
AstraZenecaFarxiga, Symbicort$528$68,49160 claims
Boehringer IngelheimJardiance$36$62,16456 claims
MerckJanuvia$71$47,11239 claims
Johnson & JohnsonXarelto$104$27,31521 claims
AbbVieSynthroid$518$4,11968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →